These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541 [TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Rosell R; Taron M; Reguart N; Isla D; Moran T Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393 [TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578 [TBL] [Abstract][Full Text] [Related]
48. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854 [TBL] [Abstract][Full Text] [Related]
50. C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib. CsToth I; Anthoine G; Berghmans T; Mascaux C; Paesmans M; Sculier JP; Meert AP Anticancer Res; 2011 Jan; 31(1):281-5. PubMed ID: 21273611 [TBL] [Abstract][Full Text] [Related]
51. Keeping It in the Family: HER3 as a Target in Brain Metastases. Kabraji S; Lin NU Clin Cancer Res; 2023 Aug; 29(16):2961-2963. PubMed ID: 37306554 [TBL] [Abstract][Full Text] [Related]
52. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC. Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450 [TBL] [Abstract][Full Text] [Related]
53. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304 [TBL] [Abstract][Full Text] [Related]
54. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613 [TBL] [Abstract][Full Text] [Related]
55. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells. Lu S; Dong Z Int J Oncol; 2017 Jun; 50(6):2113-2122. PubMed ID: 28440478 [TBL] [Abstract][Full Text] [Related]
56. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460 [TBL] [Abstract][Full Text] [Related]
57. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970 [TBL] [Abstract][Full Text] [Related]
58. [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. Zeng X; Wu SF; Zhou WX; Li DJ; Gao J; Liang ZY; Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Jul; 35(7):398-402. PubMed ID: 17069674 [TBL] [Abstract][Full Text] [Related]
59. EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor. Koo JS; Kim SH Neoplasma; 2011; 58(1):27-34. PubMed ID: 21067263 [TBL] [Abstract][Full Text] [Related]